HIV Vaccine Research Suffers Major Setback as Trump Administration Cancels Key Programme
The Trump administration has abruptly terminated a $258 million programme dedicated to developing an HIV vaccine, dealing a serious blow to global efforts to end the disease that causes AIDS. The decision affects high-profile research at Duke University and the Scripps Research Institute, where scientists were making critical progress.
NIH Terminates Funding for HIV Research at Duke and Scripps
Programme’s Termination Announced Without Public Notice
On Friday, officials from the National Institutes of Health’s (NIH) HIV division privately informed research leaders at Duke and Scripps of the funding cut. The consortia, which formed a cornerstone of U.S. efforts to develop an HIV vaccine, were deemed no longer viable by NIH leadership.
“The consortia for HIV/AIDS vaccine development and immunology was reviewed by NIH leadership, which does not support it moving forward,” said a senior agency official who requested anonymity.
Broader Impact on Vaccine Science Beyond HIV
The cancelled programme was not limited to HIV research. Scientists were leveraging its work to develop treatments for other diseases, including COVID-19, snakebite antivenom, and autoimmune disorders. The loss of funding halts this vital cross-disciplinary innovation.
Shift in Strategy: Government to Rely on Existing HIV Treatments
According to the NIH, the administration plans to shift focus toward using existing treatments to combat HIV/AIDS rather than pursuing new vaccine development. However, public health experts argue this approach undermines long-term eradication goals.
Funding Cuts Extend to Other HIV Research and Prevention Efforts
Moderna HIV Vaccine Trial Also Affected
In addition to terminating the Duke-Scripps programme, the government has also paused funding for a clinical trial of an HIV vaccine developed by pharmaceutical giant Moderna. This move adds to growing concerns among scientists and health advocates.
State-Level Prevention Programmes Withheld
The administration’s cuts have also reached state and local levels. This week, funding earmarked for HIV prevention in states and territories was withheld. In Texas, the Department of Health Services instructed grantees to pause all HIV prevention activities “until further notice.” In North Carolina’s Mecklenburg County, the health department has already laid off 10 staff members due to the budget freeze.
Global Consequences: Africa’s HIV Response Disrupted
The fallout is not limited to the United States. Several African nations that rely on U.S. research and funding support have reported serious disruptions to their own HIV prevention programmes. The cancellation threatens to derail global progress made over the last three decades.
Scientists and Experts Sound the Alarm
Dennis Burton, lead scientist at Scripps, expressed frustration at the sudden cut to what he called a “highly successful” programme.
“I find it very disappointing that, at this critical juncture, the funding for highly successful HIV vaccine research programmes should be pulled,” Burton said.
Public health experts warn that these cuts may undo years of progress in combating HIV and AIDS. With prevention efforts stalled and research curtailed, the global fight against the virus faces renewed uncertainty.
